Challenges of cell therapies for retinal diseases.

Autor:	Christelle M; INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases, Corbeil-Essonnes, France; Paris Saclay Evry U861, Corbeil-Essonnes, France. Electronic address: cmonville@istem.fr., Lise M; INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases, Corbeil-Essonnes, France; Paris Saclay Evry U861, Corbeil-Essonnes, France; CECS, Corbeil-Essonnes, France., Ben M'Barek K; INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases, Corbeil-Essonnes, France; Paris Saclay Evry U861, Corbeil-Essonnes, France; CECS, Corbeil-Essonnes, France.
Jazyk:	angličtina
Zdroj:	International review of neurobiology [Int Rev Neurobiol] 2022; Vol. 166, pp. 49-77. Date of Electronic Publication: 2022 Oct 21.
DOI:	10.1016/bs.irn.2022.09.004
Abstrakt:	Because retinal cells could not regenerate in mammals, retinal degeneration is an irreversible phenomenon caused by various disease conditions including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). During the course of these diseases, photoreceptors (PRs) are susceptible to degenerate due to their malfunctions or to a primary dysfunction of the retinal pigment epithelium (RPE). These diseases affect millions of individuals worldwide. Many therapies currently under development are designed to treat retinal pathologies and among those, cell-based replacement strategies hold significant promise for treatment of retinal degenerative diseases, especially when atrophy of retinal tissue occurs. This review will focus on the use of hPSCs to slow-down or treat retinal disorders and discuss current challenges to achieve successful engraftment of cell products. (Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu